Structure of the Lassa virus glycan shield provides a model for immunological resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 28, 2018, Pages 7320-7325

  Watanabe, Yasunori ^a,b,c   Raghwani, Jayna ^d   Allen, Joel D ^c   Seabright, Gemma E ^a,c   Li, Sai ^b   Moser, Felipe ^b   Huiskonen, Juha T ^b,e   Strecker, Thomas ^f   Bowden, Thomas A ^b   Crispin, Max ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF HELSINKI   (Finland)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Arenavirus; Glycoprotein; Glycosylation; Lassa virus; Structure

Indexed keywords

GLYCAN; GLYCOPROTEIN; MANNOSE OLIGOSACCHARIDE; GLYCOPROTEIN GP1, LASSA VIRUS; GLYCOPROTEIN GP2, LASSA VIRUS; OLIGOSACCHARIDE; VIRUS ENVELOPE PROTEIN;

ARENAVIRIDAE; ARTICLE; CONTROLLED STUDY; HUMORAL IMMUNITY; LASSA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS PARTICLE; CHEMISTRY; GLYCOSYLATION; IMMUNOLOGY;

GLYCOSYLATION; LASSA VIRUS; OLIGOSACCHARIDES; VIRAL ENVELOPE PROTEINS;

EID: 85049641362     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1803990115     Document Type: Article

References (67)

1. Ogbu O, Ajuluchukwu E, Uneke CJ (2007) Lassa fever in West African sub-region: An overview. J Vector Borne Dis 44:1–11.
2. Raabe VN, et al.; Emory Serious Communicable Diseases Unit (2017) Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever. Clin Infect Dis 65: 855–859.
3. Baize S, et al. (2009) Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J Virol 83: 5890–5903.
4. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB (2000) Effective vaccine for Lassa fever. J Virol 74:6777–6783.
5. Lukashevich IS, et al. (2008) Safety, immunogenicity, and efficacy of the ML29 re-assortant vaccine for Lassa fever in small non-human primates. Vaccine 26:5246–5254.
6. Johnson KM, et al. (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155:456–464.
7. Jahrling PB, et al. (1980) Lassa virus infection of rhesus monkeys: Pathogenesis and treatment with ribavirin. J Infect Dis 141:580–589.
8. Sommerstein R, et al. (2015) Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog 11:e1005276.
9. Crispin M, Zeltina A, Zitzmann N, Bowden TA (2016) Native functionality and therapeutic targeting of arenaviral glycoproteins. Curr Opin Virol 18:70–75.
10. Hastie KM, et al. (2017) Structural basis for antibody-mediated neutralization of Lassa virus. Science 356:923–928.
11. Li S, et al. (2016) Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike. PLoS Pathog 12:e1005418.
12. Zeltina A, Bowden TA (2017) Human antibody pieces together the puzzle of the trimeric Lassa virus surface antigen. Nat Struct Mol Biol 24:559–560.
13. Lenz O, ter Meulen J, Klenk HD, Seidah NG, Garten W (2001) The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci USA 98:12701–12705.
14. Schlie K, et al. (2010) Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication. J Virol 84:983–992.
15. Cohen-Dvashi H, Cohen N, Israeli H, Diskin R (2015) Molecular mechanism for LAMP1 recognition by Lassa virus. J Virol 89:7584–7592.
16. Bowden TA, et al. (2009) Unusual molecular architecture of the machupo virus attachment glycoprotein. J Virol 83:8259–8265.
17. Shimon A, Shani O, Diskin R (2017) Structural basis for receptor selectivity by the Whitewater Arroyo mammarenavirus. J Mol Biol 429:2825–2839.
18. Zeltina A, et al. (2017) Convergent immunological solutions to argentine hemorrhagic fever virus neutralization. Proc Natl Acad Sci USA 114:7031–7036.
19. Hastie KM, et al. (2016) Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. Nat Struct Mol Biol 23:513–521.
20. Parsy ML, Harlos K, Huiskonen JT, Bowden TA (2013) Crystal structure of Venezuelan hemorrhagic fever virus fusion glycoprotein reveals a class 1 postfusion architecture with extensive glycosylation. J Virol 87:13070–13075.
21. Igonet S, et al. (2011) X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation. Proc Natl Acad Sci USA 108:19967–19972.
22. York J, Nunberg JH (2016) Myristoylation of the arenavirus envelope glycoprotein stable signal peptide is critical for membrane fusion but dispensable for virion morphogenesis. J Virol 90:8341–8350.
23. York J, Nunberg JH (2006) Role of the stable signal peptide of Junín arenavirus envelope glycoprotein in pH-dependent membrane fusion. J Virol 80:7775–7780.
24. Eichler R, et al. (2003) Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep 4:1084–1088.
25. Oppliger J, Torriani G, Herrador A, Kunz S (2016) Lassa virus cell entry via dystroglycan involves an unusual pathway of macropinocytosis. J Virol 90:6412–6429.
26. Yoshida-Moriguchi T, Campbell KP (2015) Matriglycan: A novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 25:702–713.
27. Acciani M, et al. (2017) Mutational analysis of Lassa virus glycoprotein highlights regions required for alpha-dystroglycan utilization. J Virol 91:e00574-17.
28. Cao W, et al. (1998) Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282:2079–2081.
29. Jae LT, et al. (2014) Virus entry. Lassa virus entry requires a trigger-induced receptor switch. Science 344:1506–1510.
30. Cohen-Dvashi H, Israeli H, Shani O, Katz A, Diskin R (2016) Role of LAMP1 binding and pH sensing by the spike complex of Lassa virus. J Virol 90:10329–10338.
31. Eichler R, Lenz O, Garten W, Strecker T (2006) The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GPC. Virol J 3:41.
32. Goncalves AR, et al. (2013) Role of DC-SIGN in Lassa virus entry into human dendritic cells. J Virol 87:11504–11515.
33. Schlie K, et al. (2010) Viral protein determinants of Lassa virus entry and release from polarized epithelial cells. J Virol 84:3178–3188.
34. Lenz O, ter Meulen J, Feldmann H, Klenk HD, Garten W (2000) Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein. J Virol 74:11418–11421.
35. Illick MM, et al. (2008) Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: Implications for GP1 ectodomain shedding. Virol J 5:161.
36. Galan-Navarro C, et al. (2017) Oxidation-sensitive polymersomes as vaccine nano-carriers enhance humoral responses against Lassa virus envelope glycoprotein. Virology 512:161–171.
37. Rudd PM, Dwek RA (1997) Glycosylation: Heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 32:1–100.
38. Qian R, Chen C, Colley KJ (2001) Location and mechanism of alpha 2,6-sialyltransferase dimer formation. Role of cysteine residues in enzyme dimerization, localization, activity, and processing. J Biol Chem 276:28641–28649.
39. Kornfeld R, Kornfeld S (1985) Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54:631–664.
40. Tremblay LO, Herscovics A (1999) Cloning and expression of a specific human alpha 1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis. Glycobiology 9:1073–1078.
41. Crispin M, et al. (2014) Structural plasticity of the Semliki Forest virus glycome upon interspecies transmission. J Proteome Res 13:1702–1712.
42. Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, Doores KJ (2015) Cell- and protein-directed glycosylation of native cleaved HIV-1 envelope. J Virol 89:8932–8944.
43. Pritchard LK, et al. (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6:7479.
44. Behrens AJ, et al. (2016) Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep 14:2695–2706.
45. Coss KP, et al. (2016) HIV-1 glycan density drives the persistence of the mannose patch within an infected individual. J Virol 90:11132–11144.
46. Jardine J, et al. (2013) Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711–716.
47. Wei CJ, et al. (2010) Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design. Sci Transl Med 2:24ra21.
48. Robinson JE, et al. (2016) Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 7: 11544.
49. Andersen KG, et al.; Viral Hemorrhagic Fever Consortium (2015) Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162:738–750.
50. Jae LT, et al. (2013) Deciphering the glycosylome of dystroglycanopathies using haploid screens for Lassa virus entry. Science 340:479–483.
51. Brouillette RB, Phillips EK, Ayithan N, Maury W (2017) Differences in glycoprotein complex (GPC) receptor binding site accessibility prompt poor cross-reactivity of neutralizing antibodies between closely related arenaviruses. J Virol 91:e01454-16.
52. Mahmutovic S, et al. (2015) Molecular basis for antibody-mediated neutralization of new world hemorrhagic fever mammarenaviruses. Cell Host Microbe 18:705–713.
53. Gagneux P, Aebi M, Varki A (2015) Evolution of glycan diversity. Essentials of Glycobiology, eds Varki A, et al. (Cold Spring Harb Lab, Cold Spring Harbor, NY), 3rd Ed.
54. Huai G, Qi P, Yang H, Wang Y (2016) Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review). Int J Mol Med 37:11–20.
55. Pritchard LK, et al. (2015) Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep 11:1604–1613.
56. Van Breedam W, Pöhlmann S, Favoreel HW, de Groot RJ, Nauwynck HJ (2014) Bittersweet symphony: Glycan-lectin interactions in virus biology. FEMS Microbiol Rev 38: 598–632.
57. Dey AK, et al. (2018) cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnol Bioeng 115:885–899.
58. Reusch D, Tejada ML (2015) Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25:1325–1334.
59. Burton DR (2017) What are the most powerful immunogen design vaccine strategies? Reverse vaccinology 2.0 shows great promise. Cold Spring Harb Perspect Biol 9: a030262.
60. Stamatakis A (2014) RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30:1312–1313.
61. Drummond AJ, Suchard MA, Xie D, Rambaut A (2012) Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol 29:1969–1973.
62. Shapiro B, Rambaut A, Drummond AJ (2006) Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol Biol Evol 23: 7–9.
63. Lemey P, Minin VN, Bielejec F, Kosakovsky Pond SL, Suchard MA (2012) A counting renaissance: Combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selection. Bioinformatics 28:3248–3256.
64. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–2132.
65. Harvey DJ, et al. (2009) Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 9: 3796–3801.
66. Israeli H, Cohen-Dvashi H, Shulman A, Shimon A, Diskin R (2017) Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses. PLoS Pathog 13:e1006337.
67. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) Jalview Version 2–A multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189–1191.